Ex Parte HILLMAN - Page 14




                  Interference No. 104,436 Paper98                                                                                                                 
                  Shyamala v. Hillman Page 14                                                                                                                      
                            design of a therapeutic based on modulating MIP polypcptide activity, affecting                                                        
                            ME? gene expression, expressing genetic variants of MIP for therapeutic effect                                                         
                            such as mimicry of MIP activity or modulation of MIP activity, for example                                                             
                            inhibition of MIP activity, for the purpose of affecting a MIP mediated pathway,                                                       
                            for example an MKK3 activation pathway, or a p38 MAPK signal transduction                                                              
                            activation pathway.                                                                                                                    
                                     Gene therapy techniques can be applied in the invention for treatment of a                                                    
                            disease characterizable by excessive MEP poIypeptide mediated MKK3 activation,                                                         
                            or MIP polypeptide mediated p38 MAPK signal transduction pathway activation                                                            
                            using a genetic variant of MIP, for example a dominant negative MIP polypeptide                                                        
                            or by using a peptide inhibitor of MIP activity, for example inhibitors of MIP                                                         
                            binding to MKK3. The polynucleotide encoding the MIP polypeptide, the MIP                                                              
                            polypeptide variant, or an inhibitor of MIP activity may be engineered for                                                             
                            administration by a gene therapy protocol, provided the polynucleotide encoding                                                        
                            for example, the dominant negative or the modulator or inhibitor is capable of                                                         
                            expression in a patient.                                                                                                               
         [103] Shyamala did not, at the time of filing the provisional applications, identify any                                                                  
                            0 disease in a patient characterizable by-aberrant MIP polypeptide mediated                                                            
                                     activity;                                                                                                                     
                            0 condition diagnostically associated with overexpression of MEP by                                                                    
                                     identifying MiP transcript in brain or spleen tissues; or                                                                     
                            0 condition treatable by modulating MIP polypeptide activity, affecting MIP                                                            
                                     gene expression, or expressing genetic variants of MIP for therapeutic                                                        
                                     effect.                                                                                                                       
         [1041 Rather than simply lacking knowledge of the mechanism by which N1IP works in disease or other                                                       
                   medical conditions, Shyamala failed to identify a disease or medical condition for which MIP is                                                 
                   known to have a role.                                                                                                                           
         [105] We find no connection between these disclosures and a known real-world utility at the time of                                                       
                   filing. Shyarnala's repeated use of "may" to describe these utilities is telling because it shows that                                          
                   they are not grounded on actual knowledge.                                                                                                      








Page:  Previous  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  Next 

Last modified: November 3, 2007